Shilpa Bhatia Selected Research

EphB4 Receptor

1/2022	EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment.
1/2020	The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme.
12/2016	Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shilpa Bhatia Research Topics

Disease

30	Neoplasms (Cancer) 05/2022 - 02/2011
14	Squamous Cell Carcinoma of Head and Neck 05/2022 - 01/2014
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021 - 01/2014
4	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2013
3	Medulloblastoma 01/2017 - 04/2015
3	Melanoma (Melanoma, Malignant) 01/2016 - 01/2014
2	Pancreatic Neoplasms (Pancreatic Cancer) 04/2021 - 01/2021
2	Fibrosis (Cirrhosis) 01/2021 - 01/2019
2	Breast Neoplasms (Breast Cancer) 01/2016 - 12/2011
1	Adenocarcinoma 04/2021
1	Anaplastic Thyroid Carcinoma 01/2018
1	Laryngeal Neoplasms (Laryngeal Cancer) 02/2017
1	Cicatrix (Scar) 01/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2015
1	Sarcoma (Soft Tissue Sarcoma) 11/2015
1	Carcinogenesis 01/2014
1	Lymphatic Metastasis 01/2014
1	Prostatic Neoplasms (Prostate Cancer) 01/2012
1	Parkinson Disease (Parkinson's Disease) 01/2012
1	Carcinoma (Carcinomatosis) 12/2011
1	Aneuploidy (Aneuploid) 12/2011

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 05/2022 - 01/2014
4	Messenger RNA (mRNA)IBA 01/2018 - 04/2015
4	LigandsIBA 01/2017 - 04/2015
3	EphB4 ReceptorIBA 01/2022 - 12/2016
3	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2017
3	Phosphotransferases (Kinase)IBA 12/2016 - 04/2015
3	tyrosine receptor (receptor, tyrosine)IBA 12/2016 - 04/2015
2	Biomarkers (Surrogate Marker)IBA 05/2022 - 01/2014
2	Antisense OligonucleotidesIBA 03/2022 - 04/2021
2	CarcinogensIBA 01/2022 - 12/2011
2	CytokinesIBA 11/2021 - 01/2014
2	ChemokinesIBA 04/2021 - 01/2016
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2020 - 09/2015
2	Neoplasm Antigens (Tumor Antigens)IBA 12/2019 - 01/2012
2	Ephrin-B2 (Ephrin B2)IBA 01/2018 - 01/2017
2	EphrinsIBA 09/2015 - 04/2015
2	SynteninsIBA 01/2014 - 09/2013
1	InterferonsIBA 05/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	flt3 ligand protein (flt3 ligand)IBA 11/2021
1	DisintegrinsIBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021
1	Anaphylatoxin C5a ReceptorIBA 01/2021
1	Metalloproteases (Metalloproteinases)IBA 01/2021
1	Complement C3a (Complement 3a)IBA 01/2021
1	VimentinIBA 01/2020
1	Cadherins (E-Cadherin)IBA 01/2020
1	Collagenases (Collagenase)FDA Link 01/2019
1	atezolizumabIBA 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018
1	Cetuximab (Erbitux)FDA Link 01/2018
1	NVP-BKM120IBA 01/2018
1	EphB3 ReceptorIBA 01/2018
1	EphB2 ReceptorIBA 01/2017
1	Chemokine ReceptorsIBA 01/2016
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2016
1	Peptides (Polypeptides)IBA 01/2016
1	Recombinases (Recombinase)IBA 11/2015
1	Ephrin-A5 (AL-1)IBA 09/2015
1	EphB1 ReceptorIBA 04/2015
1	Protein Kinase InhibitorsIBA 04/2014
1	Dopamine (Intropin)FDA LinkGeneric 01/2012
1	dihydrotetrabenazineIBA 01/2012
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2012
1	Keratin-5 (Keratin 5)IBA 12/2011
1	AgarIBA 12/2011
1	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 12/2011
1	Phenobarbital (Luminal)FDA Link 12/2011

Therapy/Procedure

16	Therapeutics 01/2022 - 02/2011
13	Radiotherapy 05/2022 - 11/2015
6	Immunotherapy 05/2022 - 01/2012
2	Drug Therapy (Chemotherapy) 02/2017 - 02/2015
1	Radioimmunotherapy 11/2021
1	Laryngectomy 02/2017
1	Induction Chemotherapy 02/2017
1	Aftercare (After-Treatment) 11/2015
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2014
1	Re-Irradiation 01/2014
1	Intraperitoneal Injections 01/2012